News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Sagent Pharmaceuticals, Inc. Announces The Reintroduction Of Irinotecan Hydrochloride Injection, USP

8/5/2014 8:31:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SCHAUMBURG, Ill., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the reintroduction of Irinotecan Hydrochloride Injection, USP, an antineoplastic agent, in two preservative-free amber glass vials. According to IMS, for the 12 months ending June 2014, the US market for Irinotecan approximated $23 million. As with all products in Sagent's portfolio, Irinotecan features Sagent's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

"We are pleased to be partnering with Jiangsu Hengrui Medicine Co., an injectables leader in China, to launch Irinotecan Hydrochloride Injection, USP," said Jeffrey M. Yordon, Chief Executive Officer and Chairman of the Board. "Hengrui was the first injectable plant in China, and Irinotecan was the first injectable product, to receive FDA approval."

About Irinotecan Hydrochloride Injection, USP

Irinotecan Hydrochloride Injection, USP is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.

The package insert, available at, contains the indications, boxed warning, complete side effect profile and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.

About Jiangsu Hengrui Medicine Co.

Jiangsu Hengrui Medicine Co., Ltd is an innovative pharmaceutical company and the leading provider of antineoplastic and surgical medications in China. It is also the first Chinese company with injectable products approved by US FDA and EU Authorities. Jiangsu Hengrui Medicine Co., Ltd is listed in the Shanghai Stock Exchange and the stock code is 600276.

CONTACT: INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605 Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus